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ABSTRACT
Hepatitis C virus (HCV) is a positive sense RNA virus
that persistently infects human liver, leading to cir-
rhosis and hepatocellular carcinoma. HCV replica-
tion requires the liver-specific microRNA-122 (miR-
122). In contrast to canonical miRNA-mediated re-
pression via 3′UTR sites, miR-122 positively regu-
lates HCV replication by a direct interaction with
the 5′ untranslated region (UTR) of the viral RNA.
The protein factor requirements for this unusual
miRNA regulation remain poorly understood. Here,
we identify eIF4AII, previously implicated in miRNA-
mediated repression via 3′UTR sites, as a host fac-
tor that is important for HCV replication. We demon-
strate that eIF4AII interacts with HCV RNA and that
this interaction is miR-122-dependent. We show that
effective miR-122 binding to, and regulation of, HCV
RNA are reduced following eIF4AII depletion. We find
that the previously identified HCV co-factor CNOT1,
which has also been implicated in miRNA-mediated
repression via 3′UTR sites, contributes to regulation
of HCV by eIF4AII. Finally, we show that eIF4AI knock-
down alleviates the inhibition of HCV replication me-
diated by depletion of either eIF4AII or CNOT1. Our re-
sults suggest a competition effect between the eIF4A
proteins to influence HCV replication by modulation
of miR-122 function.
INTRODUCTION
HCV is a major cause of chronic liver disease worldwide,
infecting >184 million people (1). While the recent devel-
opment of direct acting antiviral drugs shows great promise
in HCV therapy, issues such as the high cost of these drugs
make it important that research into theHCV life cycle con-
tinues (2). Replication of the 9.6 kilobase (kb) HCV RNA
begins with translation of the viral polyprotein, driven by
an internal ribosome entry site (IRES) that directly re-
cruits the 40S ribosomal subunit and eukaryotic initiation
factor (eIF)3. Importantly, the HCV IRES does not re-
quire any components of the cap binding complex, includ-
ing eIF4A (3). The viral polyprotein is cleaved by host
and viral proteases to generate HCV structural and non-
structural proteins. The viral non-structural proteins are
essential for RNA replication, which occurs in an endo-
plasmic reticulum-derived membranous web. The RNA-
dependent RNA polymerase NS5B mediates negative and
positive sense HCV RNA synthesis (4).
The liver-specific microRNA-122 (miR-122) is essential
for HCV replication (5). miRNAs are 21–23 nucleotide (nt)
single-stranded RNA molecules expressed by most eukary-
otic organisms that generally function in animals by inter-
acting with partially complementary sites in the 3′ untrans-
lated region (UTR) ofmRNA targets, leading to translation
inhibition and mRNA degradation. miRNAs bind to tar-
gets in association with a complex of proteins known as the
RNAi-induced silencing complex (RISC), in which an Arg-
onaute protein (Ago1–4 in mammals) is the central compo-
nent (6). In contrast, miR-122 binds to two adjacent sites
in the 5′UTR of HCV RNA, upstream of the IRES, and
positively regulates viral replication (5,7). The mechanism
of regulation has been difficult to elucidate. Enhancement
of HCV IRES-driven translation by miR-122 binding was
observed in some studies (8–10). However, this was not seen
in a number of other studies, which instead found that miR-
122 binding to the HCV 5′UTR masks the 5′ nucleotides
of HCV and protects HCV RNA from degradation medi-
ated by the 5′-3′ exonucleases Xrn1 (11,12) or Xrn2 (13).
Importantly, translation regulation and/or RNA stabiliza-
tion are not sufficient to explain the full effect ofmiR-122 on
the HCV replication cycle (11,14). A recent explanation for
the missing element of miR-122 regulation was found when
miR-122 was shown to promote the switch from translation
to RNA replication by displacing poly(rC)-binding protein
2 (PCBP2) from the HCV 5′UTR (15). However, many
unanswered questions regarding the mechanism of miR-
122 regulation of HCV remain, including whether miR-122
functions in associationwith a canonical RISC andwhether
other protein factors can modulate its activity.
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miRNA-mediated repression of translation by binding to
3′UTR sites was shown to require the DEAD-box RNA
helicase eIF4AII (16). eIF4AII is a close homologue of
eIF4AI, and has generally been thought to function in an
identical fashion by unwinding 5′UTR secondary structure
within the cap-binding eIF4F complex, promoting riboso-
mal scanning and translation initiation. However, eIF4AII
is not able to functionally replace eIF4AI (17), implying that
the two proteins have different functions. A yeast two hybrid
screen for proteins that interact directly with HCV NS5B
identified eIF4AII but not eIF4AI (18). Based on this ob-
servation and the role for eIF4AII in miRNA function, we
investigated whether eIF4AII contributes to HCV replica-
tion and its regulation by miR-122.
Here, we show that eIF4AII is required for efficient HCV
replication in several different systems. eIF4AII interacts
withHCV repliconRNA and this interaction requires miR-
122.We find that eIF4AII contributes toHCV IRES-driven
translation and to its regulation by miR-122. By immuno-
precipitation, we observe a decrease in association of Arg-
onaute withHCVRNAunder conditions of eIF4AII deple-
tion, suggesting that eIF4AII is required for efficient miR-
122 recruitment to, or retention on, the viral RNA.We also
investigate the protein CNOT1, which is a host factor for
HCVand also required formiRNA-mediated repression via
3′UTR sites, and find that it contributes to the eIF4AII–
HCVRNA interaction. Finally, we show that eIF4AI deple-
tion relieves the inhibition of HCV replication by eIF4AII
or CNOT1 knockdown, suggesting eIF4AII and CNOT1
are only required for HCV replication when eIF4AI is
present. Taken together, our results identify eIF4AII as a
new host factor that is important for HCV replication, de-
scribe a novel and unexpected role for part of the eukaryotic
translation initiation machinery, and provide insight into
the little-understood role for miR-122 in HCV replication.
MATERIALS AND METHODS
Plasmids, in vitro transcription and RNA oligonucleotides
The plasmid p5′LUC3′ has been described previously (9).
pH77E1/p7 was a kind gift of Stanley Lemon (19).
Two plasmids encoding infectious HCV RNAs, pBi-Gluc-
H77C(1a)/JFH and pFL-J6/JFH1, were kind gifts of
Charles Rice (20). In vitro transcription was carried out us-
ing the T7Megascript kit (Ambion) according to the manu-
facturer’s instructions, with EcoRI-linearized p5′LUC3′ or
XbaI-linearized pH77E1/p7, pBi-Gluc-H77C(1a)/JFH1
or pFL-J6/JFH1 as templates. The capped, polyadeny-
lated Renilla luciferase transfection control RNA was
synthesized from a linearized pSV40-RL (Promega) tem-
plate using the mMessage mMachine kit (Ambion) and
polyadenylated using the Poly(A) tailing kit (Ambion). The
miRNA duplexes miR122wt and miR122p3+4, and the
2′-O-methylated oligonucleotides Rand-2’OMe and 122-
2’OMe (referred to here as control oligo and anti-miR-122,
respectively), have been described previously (9).
Cell culture, transfection and viral infection
Huh7 and Huh7.5 cells were cultured as previously de-
scribed (9). Ambion silencer select siRNAs used were
eIF4AI si (s4567), eIF4AII si1 (s4572), eIF4AII si2
(s4570) and CNOT1 si (s22844). Control si1 was an ON-
TargetPLUS non-targeting siRNA #3 purchased from
Dharmacon, and control si2 an Ambion silencer select non-
targeting siRNA (AM4613). All were delivered into cells at
10 nM final concentration using Lipofectamine RNAiMax
(Invitrogen). Cells were cultured for 72 h before harvesting.
For luciferase experiments, cells were transfected with siR-
NAs in 6 cm plates and cultured for 48 h before splitting
into 24-well plates. Transfection of 5′LUC3′ RNA, Renilla
luciferase RNA and miRNA inhibitor/duplex was carried
out using lipofectamine 2000 as described previously (9).
Cells were harvested at 6 h post transfection in Passive Ly-
sis Buffer (Promega) and luciferase activity measured with
the Dual luciferase assay system (Promega) using aGlomax
luminometer (Promega).
Electroporation was used to introduce wildtype or
mutant H77E1/p7, Bi-Gluc-H77C(1a)/JFH1 or FL-
J6/JFH1 RNA into Huh7 or Huh7.5 cells. Electropora-
tion was carried out using the Neon system (Invitrogen)
according to the manufacturer’s instructions. Where in-
cluded, siRNA treatment was for 48 h prior to electro-
poration. 4 × 105 cells were resuspended in 10 l buffer
R and mixed with 1 g wildtype or mutant H77E1/p7,
Bi-Gluc-H77C(1a)/JFH1, FL-J6/JFH1 or 5′LUC3′ RNA,
and 20 pmol anti-miR-122 where included, before elec-
troporation with a single pulse at 1300 V for 30 ms. For
immunoprecipitation experiments, three electroporations
were pooled and plated on a 10 cm plate. For Bi-Gluc-
H77C(1a)/JFH1 RNA experiments, 10% of the electropo-
rated cells were plated in each of three wells of a 24-well
plate for luciferase assays. 10 l of cell supernatant from
triplicate wells was harvested at 1, 2, 3, 4, 6 and 24 h time-
points in luciferase lysis buffer (NEB), and assayed with
Gaussia luciferase assay reagent (NEB).
For viral infection experiments, Huh7.5 cells were trans-
fected with siRNAs and cultured for 24 h before J6/JFH1
virus was added at an m.o.i. of 0.01.Media was replaced 4 h
after infection and total RNA was harvested at 48 h post-
infection.
Silvestrol (MedChemExpress) was dissolved in DMSO
and applied to cells at a final final concentration of 1Mfor
30min.When combined with siRNAknockdown, silvestrol
treatment was for 16 h.
Immunoprecipitation and western blotting
Immunoprecipitation was performed on replicon cells, or
cells electroporated with H77E1/p7 RNA and cultured
for 72 h, as described in (21), using Abcam polyclonal anti-
bodies specific to eIF4AI (ab31217) or eIF4AII (ab31218)
or the monoclonal antibody 2A8 (Sigma) to precipitate
Ago1–4. RNA was isolated from 25% of the input cell
lysate, the eIF4AI, eIF4AII or Ago1–4 immunoprecipitate,
and an isotype control IgG (Santa Cruz) immunoprecipi-
tate using TRI reagent (Sigma) and analyzed by qPCR. For
western blotting, protein samples from total cell lysates were
obtained by RIPA lysis. SDS-PAGE loading dye was added
to total cell lysate, or for immunoprecipitation experiments
to input lysate and to the immunoprecipitate, to a final con-
centration of 1×. Protein samples were separated by elec-
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trophoresis on 10% SDS-PAGE gels before semi-dry trans-
fer to PVDFmembrane. eIF4AI and II were detected using
the antibodies given above,-tubulin was detected using the
antibody ab6046 (Abcam), andAgo2was detected using the
antibody 11A9 (Millipore).
RNA isolation, northern blotting and quantitative RT-PCR
RNA was extracted using TRI reagent (Sigma) according
to the manufacturer’s protocol. Northern blot analysis of
HCV and  -actin RNA was carried out as described previ-
ously (7). Quantitative RT-PCR (qPCR) was performed us-
ing GoTaq qPCRMasterMix (Promega), following reverse
transcription using Superscript III and random primers, as
described in (21). qPCR to detect miR-122 and U6 snRNA
was carried out using specific miRNA Taqman assay kits
(Applied Biosystems) according to the manufacturer’s pro-
tocol. qPCR was carried out using a Stratagene Mx3005P
machine, and data were analyzed by the 2−Ct method rel-
ative to the actin mRNA or U6 control for total RNA ex-
periments, or as 2−Ct relative to 25% input RNA for im-
munoprecipitation experiments.
4-thio-Uridine labeling
4-thio-Uridine (4SU) labeling of newly synthesised
RNA was carried out in Huh7 cells electroporated with
H77E1/p7 RNA and plated in 10 cm plates, transfected
with eIF4AII siRNA or a non-targeting control at 24 h
post-electoporation, and labeled with 4SU at 48 h post-
transfection. 4SU was added at a final concentration of
200 M in fresh medium. Biotinylation and isolation of
4SU-labeled RNA was carried out as described in (22),
except that MTSEA-biotin-XX (Biotium) was used as
the biotinylation reagent, as described in (23). HCV and
 -actin mRNA expression in unlabeled and labeled RNA
were determined by qPCR.
Statistical analysis
All data represent mean of at least three independent bio-
logical replicates, with error bars representing standard de-
viation. Statistical analysis was carried out by two-tailed
Student’s t test for unpaired samples of equal variance. One
sample, two-tailed t test was used for data compared to a
normalized control value. *P < 0.05, **P < 0.01, ***P <
0.001.
RESULTS
eIF4AII contributes to HCV replication
To determine whether eIF4AII influences HCV replication,
initial experiments were carried out inHuh7 cells that stably
contain a bicistronic genotype 1b HCV replicon (NNeo/C-
5B) (24) (Figure 1A). siRNA transfection was used to de-
plete eIF4AI and eIF4AII. Depletion of both proteins was
effective (Figure 1B). We also confirmed the previous ob-
servation that eIF4AII protein levels increase following
eIF4AI knockdown (Figure 1B), which was shown to be
due to transcriptional induction (17). eIF4AII depletion led
to a 70% decrease in HCV RNA levels in the replicon cells
(Figure 1C), suggesting that eIF4AII contributes to HCV
replication. A smaller, but significant, decrease in HCV
RNA was observed following eIF4AI knockdown. As the
bicistronic HCV replicon contains the encephalomyocardi-
tis (EMCV) IRES, which requires eIF4A for function and
may influence its response to eIF4AI and II depletion, the
knockdown experiments were repeated in cells electropo-
rated with a monocistronic J6/JFH1 chimeric HCV RNA
that forms infectious virus (Figure 1D). This experiment
was carried out by transfecting cells with siRNAs for 72
h before the viral RNA was introduced, which allowed us
to establish whether eIF4A proteins contribute to establish-
ment of a viral replication cycle. A strong decrease in HCV
RNA was observed following eIF4AII, but not eIF4AI,
knockdown (Figure 1E), confirming that eIF4AII is a host
factor for HCV and suggesting that the reduction in HCV
RNA in replicon cells following eIF4AI knockdown is likely
to be related to the presence of the EMCV IRES. To test the
effect of eIF4AII on HCV replication in the context of viral
infection, Huh7.5 cells were transfected with siRNA target-
ing eIF4AII or a non-targeting control 24 h before infection
with J6/JFH1 virus. This experiment used a second siRNA
to eIF4AII and confirmed that eIF4AII is a host factor for
HCV replication (Figure 1F). Finally, we established that
eIF4AII depletion does not affect cell proliferation, con-
firming the results of (17) and excluding a possible indirect
effect on HCV replication due to changes in cell prolifera-
tion or viability (Supplementary Figure S1).
eIF4AII interacts with HCV RNA and miR-122
Having established that eIF4AII contributes to HCV repli-
cation, we next wished to determine whether it interacts
with HCV RNA. Cytoplasmic lysate from replicon cells
was immunoprecipitated with antibodies to endogenous
eIF4AI, eIF4AII or an isotype control. qPCR analysis
of immunoprecipitated RNA showed that HCV replicon
RNA was immunoprecipitated by the eIF4AII but not
eIF4AI or control antibodies (Figure 2A). Given the pre-
viously published role for eIF4AII in miRNA function
(16), we also tested for the presence of miR-122 in the
eIF4AII immunoprecipitate. Similar to HCV RNA, miR-
122 was found in the eIF4AII but not eIF4AI immunopre-
cipitate (Figure 2B).Western blot analysis showed that both
proteins were specifically immunoprecipitated by their re-
spective antibodies (Figure 2C), although immunoprecipi-
tation of eIF4AI was less efficient. siRNA-mediated deple-
tion of eIF4AII resulted in loss of bothHCVRNA (Supple-
mentary Figure S2A and B) and miR-122 (Supplementary
Figure S2C and D) from the eIF4AII immunoprecipitate,
confirming the specificity of the immunoprecipitation reac-
tion.
miR-122 is required for eIF4AII–HCV RNA interaction
The association of eIF4AII with both HCV RNA and
miR-122 suggested that miR-122 could contribute to the
eIF4AII–HCV RNA interaction. To examine this possibil-
ity, replicon cells were subjected to a short (6 h) treatment
with a miR-122 inhibitor (anti-miR-122) prior to eIF4AII
immunoprecipitation. We observed a reduction in the pro-
portion of HCV replicon RNA associated with eIF4AII
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Figure 1. eIF4AII contributes to HCV replication. (A) Structure of the NNeo/C-5B bicistronic replicon RNA. (B) Western blot showing effective knock-
down of eIF4AI and eIF4AII by respective siRNAs. -tubulin is shown as a loading control. Graph shows quantification of eIF4AI and eIF4AII protein
relative to -tubulin, relative to control siRNA transfection. Mean of three independent experiments, +SD. (C) HCV RNA relative to a  -actin mRNA
control was measured by qPCR in replicon cells 72h after transfection with the indicated siRNAs. Mean of 5 independent experiments, +SD. *P = 0.048,
**P = 0.0010 relative to control si, one sample Student’s t test. (D) Structure of the J6/JFH1 infectious RNA. (E) Huh7 cells were treated with eIF4AI
or eIF4AII siRNA, or a non-targeting control, for 72 h before J6/JFH1 RNA electroporation. HCV RNA relative to  -actin mRNA was measured by
qPCR at 24 h post-electroporation. Mean of 3 independent experiments, +SD. ***P = 0.0007 relative to control si, one sample Student’s t test. (F) Huh7
cells were treated with eIF4AII si2, or a non-targeting control, for 24 h before infection with J6/JFH1 virus. HCV RNA relative to  -actin mRNA was
measured by qPCR at 48 h post-infection. Mean of four independent experiments, +SD. *P = 0.014 relative to control si, one sample Student’s t test.
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Figure 2. eIF4AII interacts with HCV RNA and miR-122. RNA was extracted following immunoprecipitation of Huh7 NNeo/C-5B replicon cell cyto-
plasmic lysates with antibodies specific to eIF4AI, eIF4AII, or an IgG control. (A) HCV RNA or (B) miR-122 in the immunoprecipitates was measured
by qPCR and is shown relative to 25% input. Mean of nine independent experiments +SD. **P = 0.0089, ***P = 0.00054, Student’s t test. (C) Protein
was extracted from immunoprecipitates and analyzed by western blot with antibodies specific to eIF4AI or eIF4AII. 2% input was loaded. * indicates
non-specific IgG band.
(Figure 3A). Despite some variability in the efficiency of im-
munoprecipitation leading to high experimental error, the
ratio of HCV RNA in anti-miR-122:control treatment was
significantly lower in eIF4AII IP than in the input lysate,
showing a 60% reduction (Figure 3B). This suggests that
eIF4AII may be recruited to HCV RNA via miR-122. We
also observed a significant 64% reduction in miR-122 in
the eIF4AII immunoprecipitate compared to input follow-
ing transfection of the miR-122 inhibitor (Figure 3C and
D). This indicates that the eIF4AII interaction with miR-
122 is reduced when miR-122 function is inhibited. Finally,
we found that while eIF4AII also associates with two other
miRNAs that are highly expressed in the liver, miR-21 and
miR-26a, this interaction was not affected by miR-122 in-
hibition (Figure 3E and F). This demonstrates for the first
time that eIF4AII, which was previously shown to regu-
late miRNA function (16), also interacts with several tested
miRNAs. It also indicates that the requirement for func-
tional miR-122 is specific to the eIF4AII interactions with
miR-122 and HCV RNA.
eIF4AI depletion relieves effects of eIF4AII knockdown on
HCV RNA levels
To further investigate the regulation of HCV by eIF4AII
in a biochemically amenable system, the knockdown ex-
periments were repeated in Huh7 cells electroporated with
a monocistronic, genotype 1a H77E1/p7 RNA (Figure
4A). HCV RNA levels were analyzed by northern blot and
showed a decrease following transfectionwith both eIF4AII
siRNAs, although the effect was larger for eIF4AII si1 (Fig-
ure 4B). This confirms that eIF4AII is required for effec-
tive HCV replication. A decrease in HCV RNA follow-
ing transfection of both eIF4AII siRNAs into H77E1/p7
electroporated cells was also observed by qPCR, which
showed that HCV RNA levels were unaffected by a sec-
ond control siRNA, or by eIF4AI knockdown (Figure 4C).
We also tested the effects of transfecting cells with eIF4AI
and eIF4AII siRNA together. Interestingly, we found that
eIF4AI depletion relieved the inhibitory effects of both
eIF4AII siRNAs on HCV RNA levels (Figure 4C). West-
ern blotting confirmed effective knockdown of eIF4AII by
eIF4AII si2 and showed that eIF4AI and eIF4AII siRNAs
were both effective in the double knockdowns (Figure 4D).
To further investigate the role of eIF4AI in HCV repli-
cation, cells electroporated with H77E1/p7 RNA were
treated with the eIF4A inhibitor silvestrol. Silvestrol is a
member of the rocaglate drug family, which act by causing
eIF4A to clamp onto target RNA rather than functioning
as a helicase (25). Interestingly, silvestrol treatment led to an
increase in HCV RNA levels (Figure 4E) and eIF4AII de-
pletion no longer affected HCVRNA levels when cells were
treated with silvestrol (Figure 4F). Together, these data in-
dicate that eIF4AII is only required for HCV replication in
the presence of eIF4AI helicase activity.
H77E1/p7 RNA was immunoprecipitated with an an-
tibody to eIF4AII, but not eIF4AI (Figure 4G), confirm-
ing the eIF4AII–HCV RNA interaction shown in Figure 2
is shared by genotypes 1a and 1b and is not mediated by
the EMCV IRES in the replicon RNA. We also confirmed
that miR-122 was immunoprecipitated by the eIF4AII, but
not eIF4AI, antibody in Huh7 cells electroporated with
H77E1/p7 RNA (Supplementary Figure S3).
eIF4AII contributes to miR-122 regulation of HCV IRES-
driven translation
To dissect the stage of the HCV replication cycle that is reg-
ulated by eIF4AII, we tested whether HCV IRES-driven
translation is affected. Huh7 cells were electroporated with
a bicistronic infectious virus in which the HCV 5′UTR con-
trols production of Gaussia luciferase (Gluc) (Figure 5A).
Gluc is secreted and can be measured directly from the cul-
turemedium.Whenmeasured at early times following intro-
duction of the viral RNA before replication occurs, this re-
flects translation of the input RNA. When cells were trans-
fected with eIF4AII siRNA before electroporation, there
was a strong reduction in Gluc production. This was ob-
servable as early as 2 h post-electroporation, suggesting that
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Figure 3. eIF4AII interaction with HCV is dependent on functional miR-122. NNeo/C-5B replicon cells were treated with a miR-122 inhibitor for 6 h
prior to immunoprecipitation of cytoplasmic lysate with antibodies specific to eIF4AI, eIF4AII, or an IgG control. (A) HCV RNA levels in the immuno-
precipitates were measured by qPCR and are shown relative to 25% input. Mean of six independent experiments + SD. (B) The data in (A) are shown
as the ratio of anti-miR-122:no inhibitor for each experiment in eIF4AII IP relative to input. This ratio was reduced in the eIF4AII IP. *P = 0.029, one
sample Student’s t test. (C) As (A), except that miR-122 levels were measured by qPCR. Mean of seven independent experiments + SD. **P = 0.0079,
Student’s t test. (D) miR-122 data from (C) were analyzed as in (B). Anti-miR-122:no inhibitor ratio was reduced in eIF4AII IP compared to input. **P
= 0.006, one sample Student’s t test. (E) As (A), except that miR-21 levels were measured by qPCR. Mean of four independent experiments + SD. (F) As
(A), except that miR-26a levels were analyzed by qPCR. Mean of five independent experiments + SD.
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Figure 4. eIF4AI and eIF4AII interact to regulate replication of genotype 1a monocistronic HCV. (A) Structure of the H77E1/p7 RNA. (B) Northern
blot showing HCV RNA in Huh7 cells electroporated with H77E1/p7 RNA, then treated with a non-targeting control siRNA, an siRNA specific to
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H77E1/p7 RNAwere treated with silvestrol. *P= 0.047. Mean of three independent experiments + SD. (F) eIF4AII depletion did not affect HCVRNA
levels in cells electroporated with H77E1/p7 RNA and treated with silvestrol. Mean of three independent experiments + SD. (G) Cytoplasmic lysate
fromHuh7 cells electroporated with H77E1/p7 RNAwas immunoprecipitated with antibodies to eIF4AI, eIF4AII or an IgG control. HCV RNA levels
were determined by qPCR relative to 25% input. Mean of four independent experiments + SD. *P = 0.035, Student’s t test.
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Figure 5. eIF4AII contributes to HCV IRES-driven translation. (A) Structure of the Bi-Gluc-H77-JFH1 RNA, in which the HCV 5′UTR drives synthesis
of Gaussia luciferase. (B) Huh7.5 cells treated with siRNA specific to eIF4AI, eIF4AII or a non-targeting control were electroporated with Bi-Gluc-H77-
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eIF4AII directly modulates HCV translation (Figure 5B).
eIF4AI depletion did not affect Gluc production.
We then used the same system to test whether eIF4AII
regulates HCV translation via miR-122. Cells transfected
with eIF4AII or control siRNAs were electroporated with
the Gluc replicon RNA with or without a miR-122 in-
hibitor (anti-miR-122). miR-122 inhibition strongly de-
creased early translation mediated by the HCV IRES (Fig-
ure 5C). Following eIF4AII knockdown, the miR-122 in-
hibitor also decreased Gluc production at early timepoints,
indicating that endogenous miR-122 contributes to HCV
translation under conditions of eIF4AII depletion (Fig-
ure 5C). However, under conditions of miR-122 inhibition,
there was no significant effect of eIF4AII knockdown. This
suggests that eIF4AII only stimulates HCV translation in
the presence of endogenous miR-122. Coupled with our
observation that the eIF4AII–HCV RNA interaction re-
quires functional miR-122 (Figure 3A and B), this suggests
thatmiR-122-dependent recruitmentmight be necessary for
eIF4AII to regulate HCV translation.
To further investigate the role for eIF4AII in regulation
of HCV translation, we used a reporter system we previ-
ously developed to test the effects of miR-122 on HCV
5′UTR driven translation. This reporter consists of the fire-
fly luciferase coding region flanked by the full HCV 5′ and
3′UTRs, which is delivered into cells as an uncapped RNA
(Figure 5D) (9). Inclusion of a miR-122 inhibitor (anti-
miR-122) led to the expected decrease in luciferase activ-
ity in control siRNA-treated cells (Figure 5E), while miR-
122 overexpression (miR122wt) led to an increase in fire-
fly luciferase, confirming that miR-122 stimulates trans-
lation driven by the HCV 5′UTR. A randomized 2′OMe
oligonucleotide (control oligo) served as a control for the
miR-122 inhibitor, while miR-122 withmutations in its seed
(miR122p3+4) acted as a control for miR-122 overexpres-
sion. When this experiment was carried out in cells de-
pleted of eIF4AII, a decrease in firefly luciferase was seen
under control conditions (control oligo and miR122p3+4),
confirming that eIF4AII contributes to HCV IRES-driven
translation (Figure 5E). Conversely, eIF4AII knockdown
did not affect luciferase expression under conditions of
miR-122 inhibition (Anti-miR-122). Taken together, these
results suggest that the eIF4AII effect onHCV IRES-driven
translation is mediated at least partially by miR-122.
To assess whether the inhibitory effect of eIF4AII de-
pletion on HCV 5′UTR-driven translation could be allevi-
ated by eIF4AI knockdown, as seen for HCV replication in
Figure 4C, combined knockdown of eIF4AI and eIF4AII
was carried out before transfection of Huh7 cells with
5′LUC3′ RNA with control oligo or anti-miR-122. The in-
hibitory effect of eIF4AII knockdown on HCV 5′UTR-
driven translation was lost (Supplementary Figure S4A), al-
though this could be partly attributable to reduced transla-
tion of the cap-dependent Renilla luciferase control under
conditions of eIF4AI knockdown. We also tested whether
eIF4AII affects translation mediated by the HCV IRES
in the context of a bicistronic reporter plasmid (Supple-
mentary Figure S4B) (26). While eIF4AI knockdown in-
creased the firefly/Renilla luciferase ratio, due to inhibition
of cap-dependent Renilla luciferase translation, eIF4AII
knockdown had no effect on the ratio (Supplementary Fig-
ure S4C). As eIF4AII knockdown does not affect cap-
dependent translation (data not shown, (17)), this indi-
cates that HCV IRES-dependent translation was also un-
affected. The HCV IRES in the bicistronic plasmid lacks
the miR-122 binding region, suggesting that eIF4AII only
contributes to HCV IRES-driven translation in the context
of miR-122 regulation.
The role for miR-122 in HCV 5′UTR-driven translation
does not exclude potential additional roles in other stages
of the HCV replication cycle. To directly assess whether
eIF4AII depletion affects nascent HCV RNA synthesis,
we carried out 4-thio-uridine (4SU) labeling of Huh7 cells
electroporated with H77E1/p7 RNA and treated with
eIF4AII siRNA or a non-targeting control. This approach
allows RNA synthesized during the 4SU treatment period
to be isolated by biotinylation and strepatavidin purifica-
tion (22,23). Following 1h 4SU treatment, we observed an
equivalent decrease inHCVRNA in both the unlabeled and
labeled fractions (Figure 5F). The decrease in the labeled
fraction is in accord with the reduced availability of tem-
plate in the unlabeled fraction and indicates thatHCVRNA
synthesis is not directly affected by eIF4AII knockdown, as
has also been shown for miR-122 inhibition (27). However,
it does not exclude the possibility that eIF4AII regulates
other stages of theHCV replication cycle that are difficult to
analyze directly, such as the translation-replication switch,
in which miR-122 has been implicated (15).
eIF4AII contributes to miR-122 regulation of HCV replica-
tion
The data above suggest that eIF4AII regulates HCV trans-
lation, at least in part, by modulation of miR-122 regula-
tion. To investigate whether this also applies in the con-
text of viral replication, amiR-122 inhibitor (anti-miR-122)
and eIF4AII siRNA were introduced into replicon cells.
qPCR analysis showed a decrease inHCVRNA levels when
a miR-122 inhibitor was present in control siRNA-treated
cells (Figure 6A), as previously shown (5). However, anti-
miR-122 did not affect HCVRNA levels in eIF4AII knock-
down cells, supporting the idea that eIF4AII contributes to
miR-122 regulation of HCV replication. A similar experi-
ment was then carried out in Huh7 cells electroporated with
H77E1/p7 RNA, except that in this case the miR-122 in-
hibitor or a control oligo was transfected into cells 48 h
after siRNA transfection, to avoid any potential effects of
oligonucleotide inclusion on siRNA transfection efficiency.
Again, miR-122 inhibition led to a decrease in HCV RNA
in control siRNA-treated cells but not in eIF4AII knock-
down cells (Figure 6B).We also tested the effects of eIF4AII
depletion on replication of a miR-122-independent HCV
RNA, in which a segment of the U3 snoRNA replaces the
miR-122 binding sites (28). In both wildtype Huh7.5 and
122 mutant cells, in which miR-122 is deleted by CRISPR
(29), eIF4AII knockdown had no effect on HCV RNA lev-
els (Supplementary Figure S5).
Next, we immunoprecipitated cytoplasmic lysates of cells
containing H77E1/p7 RNA with an antibody that rec-
ognizes all four human Ago proteins. Both our group and
others have previously shown that Ago association with
HCVRNA is largelymediated viamiR-122 binding (21,29).
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Figure 6. ThemiRNAmachinery is involved in eIF4AII regulation of HCV replication. (A) NNeo/C-5B replicon cells were treated with siRNA to eIF4AII
or a non-targeting control, with or without inclusion of a miR-122 inhibitor (Anti-miR-122). HCV RNA levels were determined by qPCR relative to  -
actin mRNA at 72 h. There was no significant effect of eIF4AII knockdown in the presence of the miR-122 inhibitor. Mean of 3 independent experiments
+ SD. (B) Huh7 cells electroporated with monocistronic H77E1/p7 RNA were treated with eIF4AII si2 or control si for 48 h, then transfected with
miR-122 inhibitor or a control oligo for 24 h. Total RNA was harvested and HCV RNA levels were determined by qPCR relative to  -actin mRNA.
Mean of three independent experiments + SD. (C) The RISC was immunoprecipitated with an antibody to Ago1–4 in Huh7 cells electroporated with
monocistronicH77E1/p7RNAand treated with eIF4AII siRNAor a non-targeting control. HCVRNA levels in control IgG orAgo immunoprecipitates
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was extracted from IgG and Ago1–4 immunoprecipitates and 25% input and subjected to western blotting with an antibody to Ago2, which shows that
pulldown was specific. * indicates a non-specific band.
qPCR was used to measure the amount of HCV RNA
in Ago1–4 and control IgG immunoprecipitates relative to
25% input. We found that eIF4AII depletion reduced the
association of Ago with HCV RNA (Figure 6C). When
the ratio of HCV RNA in the Ago immunoprecipitate ver-
sus input was determined in eIF4AII knockdown cells rel-
ative to control siRNA treated cells, we observed a statisti-
cally significant 69% decrease (Figure 6D).Western blotting
confirmed the Ago IP was effective (Figure 6E). eIF4AII
knockdown did not affect the level of miR-122 (Supplemen-
tary Figure S6A) or its association with Ago1–4 (Supple-
mentary Figure S6B andC), suggesting that eIF4AII specif-
ically contributes to miR-122 recruitment to, or retention
on, HCV RNA.
We also wished to determine whether eIF4AI knock-
down could relieve the inhibition of HCV translation and
replication by a miR-122 inhibitor. Using both the Gluc
assay as a measure of translation (Supplementary Figure
S7A) and quantification of HCV RNA levels in cells elec-
troporated with H77E1/p7 RNA (Supplementary Figure
S7B), we did not observe any relief of the inhibitory ef-
fects of anti-miR-122 when cells were transfected with an
eIF4AI siRNA. Together, these data suggest that eIF4AII
is only required for HCV replication when eIF4AI is func-
tional, probably due to a role in preventing miR-122 dis-
placement by eIF4AI, but that miR-122 regulation of HCV
lies downstream of eIF4AI/eIF4AII and is thus unaffected
by eIF4AI knockdown.
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Interplay between CNOT1 and eIF4A proteins in HCV repli-
cation
The protein CNOT1 is a central component of the CCR4-
NOT deadenylase complex and has been previously identi-
fied as a host factor for HCV (30–32). CNOT1 also func-
tions in miRNA activity at 3′UTR sites, as it is recruited to
miRNA 3′UTR targets through interaction with the RISC
component TNRC6A-C, leading to mRNA deadenylation
and decay and to translational repression (33–36). An in-
teraction between the CCR4-NOT complex and eIF4AII
has also been identified (16). To investigate whetherCNOT1
is involved in eIF4AII regulation of HCV, we transfected
Huh7 cells containing the H77E1/p7 replicating RNA
with a CNOT1 siRNA and confirmed that this strongly
decreases HCV RNA levels (Figure 7A). Interestingly, we
found that inclusion of eIF4AI siRNA relieved the effect of
CNOT1 knockdown on HCV RNA levels (Figure 7A). Al-
though experimental variability meant that the effect was
not quite significant (P = 0.056), the effect size was large
(fivefold increase). This is similar to our observations with
eIF4AII knockdown (Figure 4C), suggesting that at least
part of the CNOT1 function in HCV replication may be
antagonistic to eIF4AI and that eIF4AII and CNOT1 may
regulate HCV through a common pathway. In contrast, de-
pletion of eIF4AII and CNOT1 together led to a statisti-
cally significant further decrease in HCV RNA levels com-
pared to depletion of CNOT1 alone, although the effect
size was small (Figure 7A). We also found that depletion of
CNOT1 reduced the immunoprecipitation of HCV RNA
by an eIF4AII antibody (Figure 7B). When the ratio of
CNOT1 si:control si in eIF4AII IP was compared to that in
input RNA, a significant 75% decrease was observed (Fig-
ure 7C). This suggests that eIF4AII is recruited to HCV
RNA by CNOT1 and supports the idea that eIF4AII and
CNOT1 regulate HCV via a common pathway.
DISCUSSION
Here, we identify eIF4AII as a host factor that sup-
ports HCV replication. We show that eIF4AII contributes
to HCV replication in several different viral replication
systems with different genotypes. Our data indicate that
eIF4AII regulation of HCV is modulated at least in part
via miR-122. Interestingly, we find that the closely related
protein eIF4AI does not exert the same effects on HCV,
and indeed that eIF4AI depletion or inhibition with silve-
strol relieves the inhibitory effects of eIF4AII knockdown
on HCV replication, suggesting antagonistic functions for
eIF4AI and eIF4AII.
A role for eIF4AII in miRNA-mediated translation re-
pressionwas previously identified (16). However, this is con-
troversial, as eIF4AII did not affect the silencing of mR-
NAs by tethered RISC or NOT1 (36) and CRISPR/Cas9-
mediated knockout of eIF4AII did not affect miRNA-
mediated repression (37). CNOT1 is known to be involved
in miRNA-mediated repression at 3′UTR sites, where it
functions to bring the CCR4-NOT deadenylase complex to
the targeted RNA (33–35), and the CCR4-NOT complex
was shown to interact with eIF4AII (16,38). However, other
studies showed instead that DDX6 is the factor that is re-
cruited by the RISC at miRNA-targeted 3′UTRs and both
interacts with CNOT1 and mediates translational repres-
sion (36,39–40). It is possible that these processes are dy-
namic and either eIF4AII or DDX6 may be involved, de-
pending on the cell type, physiological state, or the miRNA
and target mRNA involved. It is also possible that cells se-
lected for stable knockout of eIF4AII have developed com-
pensatory mechanisms.
Interestingly, DDX6 is also a host factor for HCV repli-
cation, although the mechanism underlying this is not clear.
DDX6 was shown to affect HCV translation in some stud-
ies (41,42), but not in others (43,44). CNOT1 was also pre-
viously identified as a host factor forHCV (30–32). eIF4AII
therefore joins DDX6 and CNOT1 in a growing list of pro-
teins that contribute to HCV replication but have also been
implicated in miRNA-mediated repression. However, it has
been difficult to demonstrate conclusively whether any of
these proteins regulate HCV via miR-122, as this is chal-
lenging to test experimentally due to the complexity of the
HCV replication cycle and the difficulties in drawing firm
conclusions from knockdown experiments. DDX6 regula-
tion of HCV was shown to be independent of miR-122
(42,43), but in a recent publication DDX6 was shown to
contribute to miR-122 regulation of HCV via the second of
its two 5′UTR binding sites (44).
In this study, we provide several lines of evidence that
support the idea that at least part of the eIF4AII regula-
tion of HCV occurs via modulation of miR-122 activity.
First, we show that the eIF4AII–HCV RNA interaction
is miR-122-dependent (Figure 3A and B), suggesting that
eIF4AII is recruited to HCV RNA via miR-122. As we
also observed a decrease in eIF4AII–HCV RNA interac-
tion following CNOT1 depletion (Figure 7B and C), it is
likely that eIF4AII is recruited via the miR-122-RISC in-
teraction with CNOT1 although further work will be nec-
essary to confirm exactly howCNOT1 and eIF4AII interact
in the regulation of HCV. Secondly, the association between
Ago andHCVRNA,which is largelymediated viamiR-122
(29), was reduced when eIF4AII was depleted, suggesting a
role for eIF4AII in miR-122-RISC binding to, or retention
on, HCV RNA (Figure 6C and D). Finally, we found that
the extent of inhibition of HCV IRES-driven translation or
HCV replication by eIF4AII depletion was reduced under
conditions of miR-122 inhibition (Figures 5 and 6). Fur-
ther work will be necessary to determine exactly how these
factors interact on HCV RNA and to characterize the re-
lationship between eIF4AII and other proteins involved in
miR-122 regulation of HCV, such as DDX6 (44), Xrn1/2
(11–13) and PCBP2 (15).
Interestingly, our results indicate that eIF4AII is only re-
quired for HCV replication in the presence of functional
eIF4AI (Figure 4C–F) and suggest that this is also true of
CNOT1 (Figure 7A). Together with our observation that
eIF4AII interacts with HCV RNA, this leads us to propose
a model in which eIF4AI and eIF4AII compete for inter-
action with HCVRNA.When eIF4AII is depleted, eIF4AI
can interact and inhibit HCV replication. eIF4AII deple-
tion reduces Ago–HCV RNA interaction (Figure 6C and
D), supporting the idea that when eIF4AII is absent eIF4AI
is recruited and displaces miR-122 from its binding sites
on HCV. Silvestrol treatment, which causes eIF4AI to bind
to target mRNAs as a clamp (25), increases HCV replica-
Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky262/4970503
by Periodicals Department user
on 18 April 2018
12 Nucleic Acids Research, 2018
A B C
Figure 7. Regulation of HCV replication by eIF4AII and miR-122 is affected by CNOT1. (A) Huh7 cells electroporated with H77E1/p7 RNA were
transfectedwith CNOT1 siRNA,with or without inclusion of the eIF4AI or eIF4AII siRNA.HCVRNA relative to a  -actinmRNA control wasmeasured
by qPCR at 72 h post-transfection. Mean of four independent experiments + SD. ***P < 0.0001, one sample Student’s t test. *P = 0.036, Student’s t test.
(B) NNeo/C-5B replicon cells were transfected with an siRNA specific to CNOT1 or a non-targeting control siRNA for 72 h before immunoprecipitation
with an eIF4AII antibody or an IgG control. RNA was extracted from immunoprecipitates and HCV RNA levels determined by qPCR. Mean of three
independent experiments + SD. (C) The data in (B) are shown as the mean ratio of CNOT1 si:control si for each experiment in eIF4AII IP relative to input,
+ SD. *P = 0.016, one sample Student’s t test.
tion and alleviates the inhibitory effects of eIF4AII deple-
tion (Figure 4E and F). We believe the most likely explana-
tion for our data is a model in which the helicase activity of
eIF4AI can displace the miR-122-RISC complex from the
HCV 5′UTR, but eIF4AII (probably binding in association
withCNOT1) competes with eIF4AI for binding and allows
miR-122 to bind to and activate translation/replication of
HCV RNA. eIF4AII depletion allows eIF4AI to displace
miR-122, resulting in reduced association ofAgowithHCV
RNA, and reduced HCV RNA levels and translation due
to a reduction in miR-122 association and therefore regu-
lation. Such displacement would explain why inclusion of
anti-miR-122 in the eIF4AII knockdown experiments does
not lead to further reduction in HCV translation (Figure
5C and E) or replication (Figure 6A and B). Further inves-
tigation will be necessary to confirm this model. A previous
indication of different functions for eIF4AI and eIF4AII
came from knockdown experiments showing that eIF4AI,
but not eIF4AII, is required for cell growth (17). The basis
for these differences has not been identified, but it is possible
that different interactions with cofactors such as CNOT1 or
eIF4G may be involved.
Our data show that eIF4AII depletion inhibits HCV
IRES-driven translation (Figure 5C and E), but does not af-
fect HCVRNA synthesis (Figure 5F). This is reminiscent of
previous observations regarding themechanism ofmiR-122
and does not exclude potential roles for eIF4AII at other
stages of the HCV replication cycle, such as the translation-
replication switch. The exactmechanism ofHCV regulation
by miR-122 remains uncertain although current data sug-
gest that it may act at multiple stages in the replication cycle.
Our data suggest that eIF4AII acts upstream of miR-122 in
the regulation of HCV, affectingmiR-122 recruitment to, or
retention at, HCV RNA but not its downstream regulatory
function. This is supported by our observation that the in-
hibitory effects of eIF4AII knockdown onHCVare relieved
by eIF4AI knockdown (Figure 4), but those of miR-122 in-
hibition are not (Supplementary Figure S7).
Finally, an analogous role for miRNAs in viral replica-
tion to that of miR-122 was recently identified for miR-
17 and let-7, which bind to bovine viral diarrhoea virus
(BVDV) RNA and stimulate viral replication (45). In con-
trast to miR-122 binding to the HCV 5′UTR, these inter-
actions occur via the 3′ UTR. It would be very interesting
to determine whether common host factors are involved in
both regulatory processes.
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